Clinical Study Of Apatinib Mesylate In Treatment Of Advanced Lung Adenocarcinoma With EGFR-TKIs Resistance

Objective:This study was to investigate the clinical efficacy and safety of apatinib mesylate in the treatment of patients with advanced lung adenocarcinoma after advanced EGFR-TKIs treatment,and to provide reference for future clinical treatment of patients with lung adenocarcinoma.Methods:From June 2016 to September 2018,a total of 68 patients with EGFR-TKIs were treated in 19 hospitals in Anhui Province after treatment with apatinib monotherapy or combination chemotherapy or conventional chemotherapy(selective pemetrexed,Clinical data of patients with advanced lung adenocarcinoma with docetaxel alone or in combination with platinum,apatinib-treated group(n=39)received oral apatinib mesylate 500 mg qd,APA methanesulfonate When combined with fentanil,dose adjustment can be made according to the patient's condition and systemic condition;the control group(n=29)uses traditional chemotherapy(select pemetrexed,docetaxel alone or combined with platinum),the dose of chemotherapeutic drugs The researcher can judge the choice according to the patient's condition.The two groups were treated for 21 days as a treatment cycle,and the short-term efficacy and adverse reactions of the two groups were evaluated every 2 cycles.Results:Clinical evaluation was performed in 68 patients,including 39 in the apatinib group and 29 in the conventional chemotherapy group.The mPFS was significantly longer in the apatinib-treated group than in the conventional chemotherapy group(5.1months vs 2.3 months,P=0.033),and the DCR was significantly higher than the conventional chemotherapy group(76.9% vs 20.7%,P=0.001);the ORR was significantly higher than the traditional one.Chemotherapy group(28.2% vs 2.4%,P=0.001).The overall adverse reaction rate was 89.7%(35/39)in the apatinib-treated group,96.6%(28/29)(P > 0.05)in the conventional chemotherapy group,and III-IV adverse reactions occurred in the apatinib group.The rate was 33.3%(13/39),compared with 13.8%(4/39)in the conventional chemotherapy group.Conclusion:Apatinib mesylate in the treatment of advanced lung adenocarcinoma patie nts with EGFR-TKIs resistance,its clinical efficacy is better than the traditional chemot herapy group,and the safety is good,can be used as a new choice for clinical treatment.